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Because of a typographical error in the erratum previously published for the article listed above, three of the study names in [Fig. 1](#F1){ref-type="fig"} were incorrect. In [Fig. 1](#F1){ref-type="fig"}*A*, "UKMD" should read "BMD." In [Fig. 1](#F1){ref-type="fig"}*B*, "USP" should read "PHS" and "BDS" should read "BMD." These errors do not affect the data. The online version reflects these changes.

![Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. *A*: Effect of aspirin on CHD events. Tests for heterogeneity: χ^2^ = 8.71, *P* = 0.367, *I^2^* = 8.2%. *B*: Effect of aspirin on risk of stroke in patients with diabetes. Tests for heterogeneity: χ^2^ = 11.0, *P* = 0.20, *I^2^* = 27.2%. BMD, British Medical Doctors; CI, confidence interval; ETDRS, Early Treatment of Diabetic Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; PHS, Physicians\' Health Study; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention Trial; and WHS, Women\'s Health Study.](zdc0011187060001){#F1}
